ARTICLE | Company News
Vernalis, RedoxTherapeutics deal
October 27, 2014 7:00 AM UTC
Vernalis granted RedoxTherapeutics exclusive, worldwide rights to develop and commercialize vipadenant ( V2006) for immuno-oncology indications. Vernalis and Biogen Idec Inc. (NASDAQ:BIIB, Weston, Ma...